ABOUT VOXNEURO

The people behind
Cognitive Function Neuroimaging.

VoxNeuro develops software that gives qualified clinicians objective EEG/ERP measurements to review alongside their clinical assessments.

Check your practice’s readinessSee your result first. Contact details optional.
Explore the sample report ↗PDF, 14 pages, no form.
Our productcfNI
cfNICognitive Function Neuroimaging
  • FDA-cleared software510(k) K253015Prescription-use software
  • Founded2017John Connolly, James Connolly and Kimberly Elliott
  • Research rootsThree decades of ERP research at McMaster UniversityThe science behind cfNI began in Dr. John F. Connolly’s lab. McMaster profile ↗

OUR STORY

Why we started VoxNeuro

VoxNeuro began with a gap that any clinician assessing cognition will recognize. The standard tools, from pen-and-paper tests to questionnaires to clinical interviews, all depend on what a patient can report and what an examiner observes. They are subjective, they vary from one examiner to the next, and they say nothing about what is happening in the brain itself while a patient attends, remembers or decides.

For more than three decades, Dr. John F. Connolly’s lab at McMaster University worked on a harder version of that problem: how to measure cognitive function in people who could not take a test at all, including patients in a coma or with severe brain injury. The answer was in the brain’s electrical activity. When a person is given a cognitive task, the brain produces measurable and reliable electrical responses, known as event-related potentials, with a timing and peak that can be recorded by EEG. That science has been described in thousands of peer-reviewed papers, but it had remained in the research lab.

In 2017, John, James Connolly and Kimberly Elliott founded VoxNeuro to bring it into everyday clinical practice. The goal was not to replace the clinician’s judgment but to give it something it had been missing: an objective, examiner-independent measurement of brain activity during cognition, normalized against a reference population, that a qualified clinician can evaluate alongside everything else they know about a patient.

Why this approach

We chose EEG/ERP for three reasons. It is built on decades of established cognitive-neuroscience paradigms, so the measures mean something to clinicians and researchers alike. It captures brain responses at the millisecond scale, which is where cognition happens. And it fits in a clinic, a hospital or mobile setting: a 20–30 minute session, needs no scanner, and produces a cloud-based report that a clinician can act on instantaneously.

That work became the Cognitive Function Neuroimaging (cfNI) Software, FDA-cleared in 2026 for use by qualified healthcare professionals in adults 18 to 70. Today VoxNeuro supports neurologists, primary care physicians, nurse practitioners and medical practices across the United States, and we still measure ourselves by the same standard we started with: give clinicians objective data they can trust while giving everyone’s brain a voice.

cfNI provides objective EEG/ERP measures to support interpretation by a qualified healthcare professional. It does not provide a diagnosis or clinical interpretation. Prescription use only.

Read McMaster’s account of VoxNeuro’s origins ↗

LEADERSHIP

Scientific expertise and experience building healthcare businesses.

John F. Connolly, PhD, Co-founder and Chief Science Officer (Emeritus)

SCIENCE

John F. Connolly, PhD

Co-founder · Chief Science Officer (Emeritus)

John is the neuroscientist behind cfNI. A professor emeritus at McMaster University and former Senator William McMaster Chair in Cognitive Neuroscience of Language, he has published more than 300 peer-reviewed papers on EEG and event-related potentials since 1982. PhD, University of London, King’s College Institute of Psychiatry.

  • Developed the EEG/ERP methodology cfNI is built on; named inventor on VoxNeuro’s foundational U.S. patent.
  • Established and chaired VoxNeuro’s Scientific Advisory Board.
  • Guided the validation research behind cfNI’s FDA 510(k) clearance.
McMaster profile ↗
Jason Flowerday, Chief Executive Officer

COMPANY LEADERSHIP

Jason Flowerday

Chief Executive Officer

Jason brings more than 25 years of executive experience across pharmaceuticals, medical devices, diagnostics and health technology, from Bayer and Johnson & Johnson to multiple CEO roles. He works closely with VoxNeuro’s board of directors and investors to build the capital formation and commercial strategies.

  • Led the company through FDA 510(k) clearance of cfNI in 2026.
  • Works directly with sales and customer success so every client has what they need.
  • Oversees clinical and research partnerships with leading U.S. institutions.
James Connolly, Co-founder and Chief Business Officer

COMMERCIAL DEVELOPMENT

James Connolly

Co-founder · Chief Business Officer

James co-founded VoxNeuro in 2017 and led it as CEO through the launch of its first product. He is usually the first person a practice talks to.

  • Leads business development, sales and partnerships with physicians, neuropsychologists and clinic owners.
  • Manages VoxNeuro’s channel partnerships and the commercial terms that make adoption practical.
  • Owns each client relationship from first conversation through contract and handoff to customer success.
Kimberly Elliott, Co-founder and Chief Operations Officer

OPERATIONS & CUSTOMER SUCCESS

Kimberly Elliott

Co-founder · Chief Operations Officer

Kim is the person clients work with every day. A VoxNeuro co-founder since 2017, she leads operations and customer success.

  • Supports every client from onboarding and technician and physician training through day-to-day questions.
  • Oversees delivery of the hardware integrations, training modules and support in every cfNI package.
  • Brings client feedback directly into product and training decisions.

FROM CLINICIANS WORKING WITH cfNI

What clinicians say about cfNI.

“In sports medicine, particularly when managing concussion, our responsibility is not simply to determine when symptoms have improved, but when an individual is truly ready to progress back to the physical, cognitive, and operational demands of sport or duty. That decision requires integrating the history, examination, functional testing, and clinical judgment rather than relying on any single measure. My collaboration with cfNI reflects that same philosophy. It provides objective, repeatable measures of brain function that add another physiologic dimension to the clinical picture. The value to me is not that cfNI replaces clinical judgment, but that it gives me better information with which to exercise it.”

Sports medicine clinician

“Neurology relies heavily on history, examination, and performance-based testing – all of which carry some degree of subjectivity. cfNI adds an objective, quantifiable measure of EEG and ERP parameters, normalized against an age-matched reference population. It doesn’t replace clinical judgment but it gives me defensible data to inform that judgment.”

Clinician, neurology

“cfNI gives me objective, quantifiable brain-function data to complement my clinical assessment. That’s something I didn’t have before Cognitive Function Neuroimaging (cfNI).”

Clinician

PRODUCT AND ACCOUNTABILITY

Clear about what cfNI provides.

FDA-cleared software

VoxNeuro’s cfNI software is FDA-cleared under 510(k) K253015. It is prescription-use software for qualified healthcare professionals, indicated for adults aged 18–70.

It does not provide a diagnosis or clinical interpretation. A qualified clinician interprets the report alongside other clinical information.

View the FDA record ↗

See what your clinicians would receive.

Explore a sample report, then discuss how assessment collection and report review could fit your practice.

QUALITY AND STANDARDS

Understand the standards behind the software.

FDA clearance, quality certification and technical standards answer different questions. Here is what each covers.

QUALITY MANAGEMENT

ISO 13485

A standard for medical-device quality management systems. It addresses the processes an organization uses to meet customer and regulatory requirements.

ISO 13485:2016 certification mark, IntertekVoxNeuro is ISO 13485:2016 certified by Intertek. Certificate 0106779, valid to November 22, 2029.

What ISO 13485 covers ↗

SOFTWARE DEVELOPMENT

IEC 62304

A standard covering medical-device software lifecycle processes, including development and maintenance.

cfNI is developed under IEC 62304.

About the software lifecycle standard ↗

RISK MANAGEMENT

ISO 14971

A framework for identifying, evaluating and controlling risks associated with medical devices, including software.

VoxNeuro applies ISO 14971 risk management to cfNI.

What ISO 14971 covers ↗

PRIVACY AND DATA HANDLING

Information your practice can evaluate.

Before implementation, clarify what patient data is collected, where it is stored, who can access it and which agreements apply.

VoxNeuro operates in compliance with HIPAA. HIPAA compliance is a regulatory obligation, not a government-issued certification; ask VoxNeuro for its security documentation and business associate agreement.

Read the privacy policy ↗